In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
暂无分享,去创建一个
M. Cannataro | P. Guzzi | P. Tassone | P. Tagliaferri | A. Giordano | A. Neri | E. Leone | M. E. G. Cantafio | N. Amodio | A. Gullà | U. Foresta | M. Lionetti | F. Conforti | M. T. Di Martino | Annamaria Gullà | Umberto Foresta | Emanuela Leone
[1] T. Chevassut,et al. The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.
[2] P. Tassone,et al. miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease , 2013, Journal of cellular physiology.
[3] N. Munshi,et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.
[4] M. Negrini,et al. Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.
[5] M. Negrini,et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma , 2012, Oncotarget.
[6] F. Morabito,et al. Targeted therapy of multiple myeloma: the changing paradigm at the beginning of the new millennium. , 2012, Current Cancer Drug Targets.
[7] P. Tassone,et al. Molecular targets for the treatment of multiple myeloma. , 2012, Current cancer drug targets.
[8] P. Tassone,et al. MicroRNAs in the pathobiology of multiple myeloma. , 2012, Current cancer drug targets.
[9] K. Podar. Novel targets and derived small molecule inhibitors in multiple myeloma. , 2012, Current cancer drug targets.
[10] P. Tassone,et al. Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma , 2012, Current cancer drug targets.
[11] P. Neri,et al. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. , 2012, Current cancer drug targets.
[12] P. Tassone,et al. Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma , 2012, Current cancer drug targets.
[13] C. Catapano,et al. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. , 2012, Cancer research.
[14] C. Croce,et al. miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ , 2012, Oncogene.
[15] L. Benetatos,et al. Deregulated microRNAs in multiple myeloma , 2012, Cancer.
[16] C. Croce,et al. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia , 2012, Oncotarget.
[17] N. Seki,et al. microRNA-1/133a and microRNA-206/133b clusters: Dysregulation and functional roles in human cancers , 2012, Oncotarget.
[18] Suhwan Chang,et al. Epigenetic control of an oncogenic microRNA, miR-155, by BRCA1 , 2012, Oncotarget.
[19] P. Kapoor,et al. Update on risk stratification and treatment of newly diagnosed multiple myeloma , 2011, International journal of hematology.
[20] Mario Cannataro,et al. Automatic summarisation and annotation of microarray data , 2011, Soft Comput..
[21] F. Slack,et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] Wen Li,et al. Clinical significance of miR-221 and its inverse correlation with p27Kip1 in hepatocellular carcinoma , 2011, Molecular Biology Reports.
[23] S. Lonial,et al. Treatment Options for Relapsed and Refractory Multiple Myeloma , 2011, Clinical Cancer Research.
[24] R. Carrasco,et al. Pathogenesis of myeloma. , 2011, Annual review of pathology.
[25] N. Munshi,et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells , 2011, Leukemia.
[26] K. Kelnar,et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.
[27] P. Pu,et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN , 2010, BMC Cancer.
[28] Y. Pekarsky,et al. Is miR-29 an oncogene or tumor suppressor in CLL? , 2010, Oncotarget.
[29] G. Ferrari,et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. , 2010, Blood.
[30] S. Lowe,et al. miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.
[31] Gabriele Sales,et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.
[32] Hansjuerg Alder,et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. , 2009, Cancer cell.
[33] C. Croce. Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.
[34] Hao Jiang,et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. , 2009, International journal of oncology.
[35] Lu Jiang,et al. MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. , 2009, Cancer genomics & proteomics.
[36] P. Tassone,et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo , 2009, Cancer biology & therapy.
[37] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[38] P. Tassone,et al. In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor , 2008, British journal of haematology.
[39] Tyler E. Miller,et al. MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ , 2008, Journal of Biological Chemistry.
[40] C. Croce,et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma , 2008, Oncogene.
[41] C. Croce,et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer , 2008, Oncogene.
[42] S. K. Zaidi,et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. , 2008, Cancer research.
[43] C. Croce,et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. , 2007, Endocrine-related cancer.
[44] Giovanni Vanni Frajese,et al. miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.
[45] Reuven Agami,et al. Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation , 2007 .
[46] P. Tassone,et al. Novel therapeutic approaches based on the targeting of microenvironment-derived survival pathways in human cancer: experimental models and translational issues. , 2007, Current pharmaceutical design.
[47] W. Lamph,et al. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer. , 2006, Cancer letters.
[48] R. Terracciano,et al. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? , 2006, European journal of cancer.
[49] F. Slack,et al. Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.
[50] N. Munshi,et al. Proteasomal Degradation of Topoisomerase I Is Preceded by c-Jun NH2-Terminal Kinase Activation, Fas Up-Regulation, and Poly(ADP-Ribose) Polymerase Cleavage in SN38-Mediated Cytotoxicity against Multiple Myeloma , 2004, Cancer Research.
[51] V. Ambros. The functions of animal microRNAs , 2004, Nature.
[52] P. L. Bergsagel,et al. Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.
[53] Lin He,et al. MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.
[54] C. Croce,et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[55] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[56] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[57] C. Li,et al. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[58] A I Pick,et al. THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.
[59] Reuven Agami,et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. , 2007, The EMBO journal.
[60] Wh Sit,et al. Cancer Genomics & Proteomics , 2007 .
[61] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.